Compare SSRM & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | WGS |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.6B |
| IPO Year | 1996 | N/A |
| Metric | SSRM | WGS |
|---|---|---|
| Price | $21.91 | $150.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $21.89 | ★ $135.00 |
| AVG Volume (30 Days) | ★ 2.2M | 453.1K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.05 | 0.07 |
| Revenue | ★ $1,431,099,000.00 | $402,190,000.00 |
| Revenue This Year | $58.80 | $41.17 |
| Revenue Next Year | $45.35 | $23.53 |
| P/E Ratio | ★ $21.16 | $2,102.42 |
| Revenue Growth | 30.30 | ★ 50.50 |
| 52 Week Low | $6.79 | $55.17 |
| 52 Week High | $25.98 | $170.87 |
| Indicator | SSRM | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 51.75 |
| Support Level | $20.81 | $156.17 |
| Resistance Level | $23.15 | $165.62 |
| Average True Range (ATR) | 0.93 | 7.38 |
| MACD | 0.09 | -1.79 |
| Stochastic Oscillator | 41.54 | 12.04 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.